Monographie - Ganciclovir sodium

Utolsó frissítés :
08/05/2024

Ganciclovir sodium

Kémiai szerkezet

Kereskedelmi név

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Ceptyl	Mexikó
Ciganclor	Argentína
Citovirax	Olaszország
Cymevan	Franciaország
Cymeven	Németország
Cymevene	Ausztrália, Ausztria, Belgium, Brazília, Chile, Colombia, Dánia, Ecuador, Egyesült Arab Emírségek, Egyiptom, Finnország, Görögország, Hollandia, Horvátország, Irán, Írország, Izland, Lengyelország, Luxemburg, Magyarország, Malaysia, Mexikó, Nagy-Britannia, Norvégia, Olaszország, Orosz, Peru, Portugália, Spanyolország, Svájc, Svédország, Törökország, új-Zéland, Venezuela
Cymevir	Brazília
Cytovene	Amerikai Egyesült Államok, Kanada
Ganciclovir	Amerikai Egyesült Államok, Argentína, Chile, Ecuador, Franciaország, Kanada, Mexikó, Németország
Gavir	India
Inglav	Mexikó
Natclovir	India
Pharcigave	Mexikó
Umecortil	Colombia, Mexikó
Viraprex	Mexikó

Irodalom : Ganciclovir sodium

	Type	Publikáció
3	Napló	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
4	Napló	Zazempa V, Morgenszejn J, Paul M, Astier A. Reconstitution centralisée du ganciclovir : méthode de contrôle et étude de stabilité. Act Pharm Biol Clin 1995 ; 8: 525-528.
36	Napló	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
59	Napló	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
67	Napló	Outman WR, Mitrano FP, Baptista RJ. Visual compatibility of ganciclovir sodium and parenteral nutrient solution during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 1538-1539.
69	Napló	Visor GC, Lin LH, Jackson SE, Winterle JS, Lee G, Kenley RA. Stability of ganciclovir sodium (DHPG sodium) in 5% dextrose or 0.9% sodium chloride injections. Am J Hosp Pharm 1986 ; 43: 2810-2812.
70	Napló	Silvestri AP, Mitrano FP, Baptista RJ, Williams DA. Stability and compatibility of ganciclovir sodium in 5% dextrose injection over 35 days. Am J Hosp Pharm 1991 ; 48: 2641-2643.
72	Napló	Johnson CE, Jacobson PA, Chan E. Stability of ganciclovir sodium and amino acids in parenteral nutrient solutions. Am J Hosp Pharm 1994 ; 51: 503-508.
73	Napló	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
74	Napló	Mulye NV, Turco SJ, Speaker TJ. Stability of ganciclovir sodium in an infusion-pump syringe. Am J Hosp Pharm 1994 ; 51: 1348-1349.
76	Napló	Parasrampuria J, Li LC, Stelmach AH, Sykes TR, Gordon GA. Stability of ganciclovir sodium in 5% dextrose injection and in 0.9% sodium chloride injection over 35 days. Am J Hosp Pharm 1992 ; 49: 116-118.
81	Napló	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Napló	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
88	Napló	Mole L, Oliva C, O?Hanley P. Extended stability of ganciclovir for outpatient parenteral therapy for cytomegalovirus retinitis. J Acquired Immune Defic Syndr 1992 ; 5: 354-358.
99	Napló	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Napló	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
201	Napló	Thompson DF, Allen LV, Stiles ML. Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2530-2531.
244	Napló	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
245	Napló	Phaypradith S, Vigneron J, Perrin A, Durney-Archeray MJ, Hoffman MA, Hoffman M. Stability of ganciclovir sodium (Cymevan*) after dilution in PVC infusions and polypropylene syringes. J Pharm Belg 1992 ; 47: 494-498.
248	Napló	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Napló	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Napló	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
299	Napló	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Napló	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Napló	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Napló	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Napló	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
479	Napló	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
492	Napló	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Napló	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
604	Laboratórium	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
905	Napló	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Napló	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1410	Napló	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Napló	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Napló	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1625	Napló	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1754	Napló	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1925	Napló	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Napló	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Napló	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247	Napló	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3626	Laboratórium	Tacrolimus (Prograf®) - Résumé des Caractéristiques du Produit Astellas Pharma 2014
3662	Laboratórium	Foscavir (Foscarnet®) - Summary of Product Characteristics Clinigen 2014
3728	Napló	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3791	Poszter	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3796	Napló	Morlet N, Young S, Naidoo D et al. High dose intravitreal ganciclovir for CMV retinitis: a shelf life and cost comparison study. Br Ophtalmol 1995 ; 79: 753-755.
3883	Laboratórium	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
4021	Napló	Guichard N, Bonnabry P, Rudaz S, Fleury S. Long-term stability of ganciclovir in polypropylene containers at room temperature. J Oncol Pharm Practice 2017 ;25,2: 303-308
4521	Napló	Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020

Mentions Légales